General Proximity Secures $9 Million Grant for Innovative Cancer Treatment Technology
General Proximity Receives CPRIT Funding for Cancer Innovation
In a significant boost for cancer research, General Proximity, a pioneering biotechnology firm focused on the development of innovative therapies, has been awarded a substantial $9 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). This grant aims to further advance their proprietary OmniTAC™ induced proximity platform, a groundbreaking technology designed to tackle cancer targets that have historically been deemed beyond reach for conventional treatments.
The OmniTAC™ platform employs a novel approach that leverages small molecules to bring two proteins into close proximity, effectively inducing a desired therapeutic outcome. This method opens doors to targeting proteins that have long been considered 'undruggable.' By enabling unbiased identification of effector proteins that manipulate disease-relevant targets, OmniTAC™ stands poised to redefine the landscape of cancer treatment.
General Proximity has positioned itself uniquely in the pharmaceutical landscape. The company’s commitment to developing next-generation induced proximity medicines has garnered recognition and support, making it the only company to receive a grant in the new technology category during this funding cycle. The support from CPRIT underscores the potential of this innovative approach, highlighting confidence in the application of induced proximity technology in oncological therapies.
Dr. Armand B. Cognetta III, the Founder and CEO of General Proximity, expressed his gratitude for the recognition, stating, _“We are honored to receive this support from CPRIT, which underscores the potential of our OmniTAC™ platform and offers a glimpse into the future of cancer treatment.”_ He further noted that the grant will facilitate the progression of their lead oncology program into clinical trials, thus translating their innovative research into practical applications for patients.
The CPRIT grant will not only enhance General Proximity’s research capabilities but also assist in validating the OmniTAC™ platform through clinical trials. This aligns with CPRIT's mission to fund innovative projects that promise significant benefits for cancer patients. Out of 207 total applications, General Proximity emerged victorious alongside only a handful of select projects in their category, further solidifying their unparalleled approach within the biotech sphere.
Cancer has long presented unique challenges due to the nature of its targets; many cancer drivers, including tumor suppressors, become either lost or inactivated, rendering them undruggable through traditional means. The OmniTAC™ platform's core functionality systematically identifies effector proteins that can interact with these challenging targets, allowing for a new avenue of intervention.
General Proximity's advancements, empowered by this funding, may reveal strategies that could change the therapeutic landscape. Indeed, the company is already advancing multiple preclinical programs derived from the OmniTAC™ platform, signalling a promising future for its applications across various therapeutic domains, including oncology.
In addition to enhancing its research and development capabilities, General Proximity also looks forward to expanding its presence in Texas. The company is dedicated to fostering partnerships with Texas clinical sites and becoming an integral part of the state's life sciences ecosystem—an environment ripe for innovation in medical research and patient care.
For more information on General Proximity and their cutting-edge research efforts, visit www.generalproximity.bio.
About CPRIT
Founded by the Texas Legislature and approved by voters in 2007, CPRIT is Texas's primary authority for advancing cancer research and innovation. With a remarkable commitment from the state, CPRIT has allocated over $6 billion in funding to fuel advancements in cancer research and prevention efforts. The institute's continuous support has drawn in top talent and innovative companies to Texas, fostering an environment where groundbreaking cancer solutions can flourish.
Through its initiatives, CPRIT has successfully awarded over $4 billion in grants to various Texas-based research institutions, aiding in recruitment, establishing new companies, and delivering millions of cancer prevention services statewide. This record of success underscores their commitment to combating cancer through innovation, education, and actionable solutions.